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Abstract
Background: Steroid hormones influence mitogenic signaling pathways, apoptosis, and cell cycle checkpoints, and it has
long been known that incidence of bladder cancer (BC) in men is several times greater than in women, a difference that
cannot be attributed to environmental or lifestyle factors alone. Castration reduces incidence of chemically-induced BC
in rodents. It is unclear if this effect is due to hormonal influences on activation/deactivation of carcinogens or a direct
effect on urothelial cell proliferation or other malignant processes. We examined the effect of castration on BC growth
in UPII-SV40T transgenic mice, which express SV40 T antigen specifically in urothelium and reliably develop BC.
Furthermore, because BC growth in UPII-SV40T mice is exophytic, we speculated BC growth was dependent on
angiogenesis and angiogenesis was, in turn, androgen responsive.
Methods: Flat panel detector-based cone beam computed tomography (FPDCT) was used to longitudinally measure
exophytic BC growth in UPII-SV40T male mice sham-operated, castrated, or castrated and supplemented with
dihydrotestosterone (DHT). Human normal bladder and BC biopsies and mouse bladder were examined quantitatively
for thrombospondin-1 (TSP1) protein expression.
Results: Mice castrated at 24 weeks of age had decreased BC volumes at 32 weeks compared to intact mice (p = 0.0071)
and castrated mice administered DHT (p = 0.0233; one-way ANOVA, JMP 6.0.3, SAS Institute, Inc.). Bladder cancer cell
lines responded to DHT treatment with increased proliferation, regardless of androgen receptor expression levels. TSP1,
an anti-angiogenic factor whose expression is inhibited by androgens, had decreased expression in bladders of UPII-
SV40T mice compared to wild-type. Castration increased TSP1 levels in UPII-SV40T mice compared to intact mice. TSP1
protein expression was higher in 8 of 10 human bladder biopsies of normal versus malignant tissue from the same
patients.
Conclusion: FPDCT allows longitudinal monitoring of exophytic tumor growth in the UPII-SV40T model of BC that
bypasses need for chemical carcinogens, which confound analysis of androgen effects. Androgens increase tumor cell
growth in vitro and in vivo and decrease TSP1 expression, possibly explaining the therapeutic effect of castration. This
effect may, in part, explain gender differences in BC incidence and implies anti-androgenic therapies may be effective in
preventing and treating BC.
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Racial and gender differences in bladder cancer (BC) inci-
dence and survival were recently reviewed by Madeb and
Messing [1]. BC is the fifth most common non-cutaneous
cancer in the United States with over 67,000 newly diag-
nosed cases projected for 2007 [2]. Men are much more
likely to be diagnosed with BC than women. Between
1992 and 2002, the incidence ratio for men relative to
women by race ranged from 2.68 for African Americans to
4.26 for Native Americans. The male to female incidence
ratio is remarkably consistent despite more than four-fold
variation in incidence across race [3]. It is tempting to
attribute the sexual incidence difference to environmental
or lifestyle factors; however, the ratio has remained
unchanged while women have entered the male work-
place, and the incidence of smoking and smoking related
diseases in females has increased considerably compared
to that in men in most racial and demographic groups. It
is unlikely that a purely environmental exposure etiology
explains the differences between the genders in develop-
ing BC. A recent examination of BC risk in the United
States Nurses Health Study cohort found an increased risk
of BC in women associated with early age at menopause
[4]. Of note is that many putative bladder carcinogens are
activated or inactivated by cytochrome P450 enzymes,
many of which are influenced by androgens [5-9].
Chemical carcinogenesis studies on mice have shown that
males more readily develop BC than females, but that dif-
ference was nullified by castrating males. Testosterone
given to castrated males decreased time to BC induction to
rates of intact males [10]. In addition, the incidence of
chemically-induced BC in male rats was increased by tes-
tosterone and decreased by estrogen supplementation
[11]. Importantly, bladder carcinogenesis in rodents can
be reduced by administration of luteinizing hormone-
releasing hormone (LH-RH) agonists, the anti-androgen
flutamide, and the 5-alpha reductase inhibitor finasteride
[12]. More recently, androgen receptor (AR) knock-out
(ARKO) and castrated male mice had a lower incidence of
BC than wild-type male mice when given chemical carcin-
ogens [13]. The gender and hormone dependent differ-
ences in chemically-induced BC might be attributed to
sexual differences in activation or deactivation of carcino-
gens both in the bladder epithelium and in remote sites,
or they might be due to sexual differences in regulation of
a variety of relevant molecular processes such as cellular
proliferation or response to DNA damage in the targeted
tissue. Here we examine the question using a transgenic
mouse model of BC that is not dependent on administra-
tion of carcinogens. The UPII-SV40T transgenic mouse
model expresses the SV40 large T antigen specifically in
the urothelium and reliably develops BC [14].
Thrombospondin-1 (TSP1) is a secreted protein that
forms a 450-kDa homotrimer. Originally, TSP1 was iden-
tified as a component of platelet α granules [15,16], but
TSP1 is now also known to be secreted by a variety of dif-
ferent cells including vascular smooth muscle [17],
fibroblasts [18], and endothelial cells [19,20]. There are
three different subgroups of thrombospondins: Subgroup
A includes TSP1 and TSP2 which form homotrimers; Sub-
group B includes TSP3, TSP4, and TSP5/COMP which
form homopentamers [21]; and Subgroup C includes
TSPs in insects which form pentamers but have distinct N-
terminal domains [22]. Highly conserved among these
subgroups is the carboxy end, which includes three EGF-
like domains (called TSP Type 2 repeats), seven calcium-
binding domains (TSP Type 3 repeats), and a globular C-
terminal domain that is involved in cell binding. TSP1
and TSP2 also include, closer to the N-terminal end, three
TSP Type 1 repeats (TSR, properdin), which have been
implicated in signaling angiogenic inhibition through
CD36 binding and support attachment of other cell types
[[23,24]; see reviews]. The review by Adams and Lawler
[25] summarizes that the angiogenic inhibitory action of
TSP1 is mediated through inhibition of endothelial cell
migration, induction of endothelial cell apoptosis, and
inhibition of "growth factor mobilization and access to
the endothelial cell surface."
Digestion of TSP1 with chymotrypsin results in several
fragments, one of which is a 50 kDa N-terminal fragment
that includes a procollagen homology domain and the
Type 1 and Type 2 repeats [26]. This 50-kDa fragment was
found to inhibit rat corneal neovascularization in vivo and
endothelial cell migration in vitro [26]. Furthermore,
active peptides derived from this 50 kDa fragment, from
the procollagen and Type 1 repeat domains, were also
found to block in vivo neovascularization [26]. These same
TSP1 active peptides have been shown to bind to CD36,
and neutralizing antibodies to CD36 were able to block
native TSP1 and active peptide fragments from inhibition
of endothelial cell migration [27]. Furthermore, TSP1
inhibition of corneal neovascularization was impaired in
CD36 null animals [28]. In a review, Armstrong et al. [22]
summarize a signal-transduction pathway in which a
TSP1-stimulated CD36, an 88 kDa transmembrane glyco-
protein, phosphorylates kinases p38 and JNK to induce
transcription of FasL, which, when bound to Fas, leads to
activation of caspases and results in apoptosis.
Low levels of TSP1 in human BC (by immunohistochem-
istry) were associated with low nuclear p53, increased
tumor recurrence and progression, and decreased survival
[29,30]. Cultured media from human BC cell lines stimu-
lates migration and neovascularization and has decreased
concentrations of TSP1 compared to media from normal
urothelium, which actually inhibited these activities [31].Page 2 of 17
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androgen-responsive tissues in rodents. Castrated male
rats had increased expression of TSP1 and decreased
microvessel density in the prostate, which could be
reversed by administration of testosterone [32]. Treating
mouse breast cancer cells with testosterone decreased de
novo TSP1 synthesis (thus decreasing TSP1 expression at
the mRNA and protein levels), and this effect was abro-
gated by administration of the anti-androgen flutamide
[33], suggesting androgen-regulated angiogenesis. Here,
we investigate the expression of TSP1 in human BC tissues
and the influence of the androgenic milieu on TSP1
expression and BC growth in UPII-SV40T mice.
Methods
Animals
UPII-SV40T transgenic mice on FVB/N background (gift
from Drs. Tung-Tien Sun and Xue-Ru Wu, New York Uni-
versity, NY) utilize the uroplakin II promoter to express
simian virus 40 large T antigen specifically in the urothe-
lium and reliably develop BC [14]. Animals were main-
tained in a pathogen-free facility where all care,
experimental procedures, and euthanasia were performed
in accordance with the policies set forth by the University
Committee of Animal Resources at the University of
Rochester Medical Center in compliance with federal
guidelines.
Genotyping
Tail biopsies were obtained from animals at weaning.
DNA was extracted from the tails using an alkaline lysis
solution (25 mM NaOH, 0.2 mM EDTA, pH 12.0) at 95°C
for 1 hour followed by neutralization with an equal vol-
ume of 40 mM Tris-HCl at pH 5.0. The primer sequences
for a ~ 500 bp SV40 T antigen product were GGACAAAC-
CACAACTAGAATGCAGTG and CAGAGCAGAATTGT-
GGAGTGG. PCR cycling conditions were 94°C for 5
minutes followed by 12 cycles of 94°C for 20s, 64°C
(decreasing by 0.5°C every cycle) for 30s, 72°C for 35s,
then 25 cycles of 94°C for 20s, 58°C for 30s, 72°C for
30s, and a 10-minute final extension. Western blots for
SV40 T in transgenic mouse bladders validated the PCR
screening procedure (described in "Immunoblotting").
Castration
UPII-SV40T transgenic male mice were randomized and
either castrated (8 animals), castrated with the addition of
a 60-day controlled release 1.5 mg dihydrotestosterone
(DHT) pellet (Innovative Research of America, Sarasota,
FL) (6 animals), or subjected to sham operations (9 ani-
mals) at 24 weeks of age after an initial flat panel detector-
based cone beam computed tomography (FPDCT) scan.
Wild-type and UPII-SV40T transgenic male mice were
sham operated or castrated for analysis. Animals were
administered 1 mg/ml acetaminophen ad libitum in drink-
ing water for 24 hours prior to and following recovery sur-
gery. Animals were anesthetized via isoflurane inhalation
in an induction chamber and remained anesthetized
throughout the procedure by using a nose-cone. Hair was
removed from the scrotum with an electric shaver, and the
area was swabbed with betadine followed by 70% etha-
nol. Gentle pressure was applied to the abdomen to cause
the testes to descend into the scrotum. An axial incision of
the scrotum was made midway between the anus and the
penis. A small incision was made to the underlying fascia.
Forceps were used to gently pull the testis through the
incision. A slipknot of suitable resorbable suture material
was placed around the vas deferens near the testis as a
temporary tourniquet, which remained as an internal
suture. The vas deferens was then cut between the suture
and the testis, and the testis was removed. The incision
was closed with suitable non-resorbable suture material in
a simple interrupted pattern and again swabbed with
betadine. Body temperature was maintained via the use of
a warming pad. Animals were returned to cages and mon-
itored until they could eat, drink, and ambulate normally.
Sham operations included all physical manipulations
except the internal sutures and removal of the testes.
Flat panel-based cone beam computed tomography
UPII-SV40T transgenic mice were administered tail vein
injections of 0.15 cc Omnipaque™ (Iohexol), anesthetized
via isoflurane inhalation for 15 minutes, and scanned as
previously described [34-36] at 24, 28, and 32 weeks of
age. The 290 2D images acquired in each 10-second 360°
scan were reconstructed by a filtered back projection-
based modified Feldkamp algorithm and analyzed with
Amira, version 3.1.1-1, for MacOSX [36]. In addition,
reconstructed data sets were also visualized and tumor
volumes calculated in ImageJ 1.36b (NIH, USA). Tumor
volumes were calculated from the difference in areas in
each slice after thresholding images to select the bladder
area and the Omnipaque™-filled area. Mean tumor vol-
umes between groups were compared using one-way
ANOVA and t-test (JMP 6.0.3, SAS Institute Inc., Cary,
NC).
Immunohistochemistry
Five μm sections of formalin-fixed, paraffin-embedded
mouse bladders from intact, castrate, and castrate + DHT
UPII-SV40T male mice at 32 weeks of age were mounted
and dried on glass slides. The slides were dried, baked at
57°C overnight, and deparaffinized. Endogenous peroxi-
dase activity was quenched by incubation in 0.3% hydro-
gen peroxide in PBS for 30 minutes. Antigen unmasking
was performed by 25-minute microwave incubation in 10
mM citrate buffer (pH 6.0). Slides were incubated at room
temperature for one hour with: rat anti-CD34 (1:50;
Abcam 8158, Cambridge, MA), rabbit anti-SV40T (1:100;
Santa Cruz 20800, Santa Cruz, CA), mouse anti-TSP1Page 3 of 17
(page number not for citation purposes)
BMC Urology 2008, 8:7 http://www.biomedcentral.com/1471-2490/8/7(1:400; Neomarkers Ab-4, Clone A6.1, Fremont, CA), or
rabbit anti-AR (1:100; Santa Cruz 815). Secondary anti-
bodies were peroxidase conjugated. CD34, SV40T, and AR
were detected with DAB (Dako, Carpinteria, CA) for 10
minutes. TSP1 was detected with AEC+ (Dako) for 10
minutes. Slides were then counterstained in Modified
Mayer's Hematoxylin, blued in 3% ammonia, rinsed in
tap water, and mounted. Hematoxylin/eosin slides were
also prepared. Slides were viewed at 100× or 200× original
magnification with a light microscope.
Five μm sections of formalin-fixed, paraffin-embedded
urothelial biopsies from ten male cancer patients (9 high-
grade T2–T4, 4 with lymph node involvement, 5 with
metastases; 1 low-grade Ta, with lymph node involve-
ment) with foci of benign urothelium were mounted and
dried on chemically charged slides, followed by baking at
57°C overnight, deparaffinization, and quenching of
endogenous peroxidase activity by incubating in 3%
hydrogen peroxide for 6 minutes. The peroxide was
cleared from the slides by rinsing in running water then
TBS (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20,
pH 7.6). Antigens were unmasked by 12-minute heat
retrieval in citrate buffer, pH 6.1 (Dako) using the Borg
Decloaking Chamber (Biocare Medical, Walnut Creek,
CA) set to 120–123°C, 18–21 psi. After antigen unmask-
ing, slides were allowed to cool for 15 minutes prior to
staining, rinsed in TBS for 5 minutes, and placed on a
DAKO autostainer. Slides were exposed at room tempera-
ture to mouse monoclonal anti-AR antibody (Dako, clone
AR441, 1:25) for 60 minutes, Horse Anti-Mouse IgG
Biotin (Vector Laboratories, Burlingame, CA) for 30 min-
utes, and Streptavidin-HRP (Jackson Labs, West Grove,
PA) for 30 minutes. A 10-minute AEC+ (Dako) incuba-
tion was used to develop slides, followed by rinsing in dis-
tilled water, counterstaining in Modified Mayer's
Hematoxylin, bluing in 3% ammonia, rinsing in tap
water, and mounting with aqueous mounting media.
Slides were viewed at 400× original magnification with a
light microscope.
Mouse bladder cancer explant
A tumor-bearing male UPII-SV40T (MMUST) transgenic
animal was sacrificed, and the entire bladder was removed
intact and placed in sterile PBS. The bladder was rinsed in
sterile PBS before transferring to sterile DMEM. In DMEM,
the bladder was bisected, and the urothelium (inner layer
of the bladder) was scraped out with a scalpel, finely
minced, and cultured in DMEM supplemented with 10%
FBS, 2 mM L-glutamine, and penicillin (100 u/ml)/strep-
tomycin (100 μg/ml), 2.5 μg/ml fungizone in a humid
5% CO2 chamber at 37°C. This explant was maintained in
culture for six months. RT-PCR for cytokeratins 13 and 20
were performed to, respectively, confirm transitional-type
and terminally differentiated urothelium [37].
Tissue culture
Human prostate cancer (LNCaP, PC3; ATCC, Manassas,
VA), human BC (J82-male, TCCSUP-female; ATCC), and
UPII-SV40T bladder cancer explant (MMUST) were main-
tained in 10% FBS and assayed in 5% charcoal-stripped,
dextran-treated FBS at 37°C in phenol red-free DMEM 2
mM L-glutamine, and penicillin (100 u/ml)/streptomycin
(100 μg/ml) in a humid 5% CO2 incubator.
Cell proliferation assay
Cells were cultured in 12-well plates with the addition of
ethanol (0.001%) or DHT in ethanol vehicle at final con-
centration of 1 nM or 10 nM DHT for 72 hours with
media change and treatment replenishment after 48
hours. After 72 hours of DHT or ethanol treatment, 100 μl
of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, Sigma) stock solution (5 mg/ml) was
added to each 1 ml media in the wells and incubated at
37°C for three hours, followed by addition of 1 ml of
0.04N HCl in isopropanol at room temperature with agi-
tation for 15 minutes. Absorbance was read at 570 nm
with a background absorbance at 660 nm. Experiments
were performed in triplicate, and mean absorbance ± the
standard error was calculated in Microsoft® Excel (Micro-
soft Corporation, Redmond, WA).
Immunoblotting
Whole bladders and a panel of organs from 20–24 week-
old mice and frozen biopsies of human normal bladder
and cancer (paired from the same patient) were homoge-
nized in 1× RIPA lysis buffer with added protease inhibi-
tors (Sigma, P8340, St. Louis, MO). Human samples
(different than those used for IHC) were obtained from
10 males ranging in age from 60–81 years. All patients
had high grade, invasive urothelial carcinomas (3 meta-
static), and samples were obtained with informed consent
and University of Rochester Research Subject Review
Board approval of the protocol. Normal urothelium and
BC specimens were identified by experimental urologists
and genitourinary pathologists.
Cell cultures were scraped in PBS, centrifuged, and resus-
pended in 1× RIPA lysis buffer with added protease inhib-
itors. Proteins were separated by SDS-PAGE on 7.5%
acrylamide gels. Proteins were transferred to a nitrocellu-
lose membrane, blocked overnight at 4°C in 5% milk,
incubated with goat anti-human N-terminal TSP1
(diluted 1:200; Santa Cruz 12312), rabbit anti-AR
(diluted 1:200; Santa Cruz 815; cross-reacts with mouse
and human), mouse anti-AR (diluted 1:200; Dako, clone
AR441; cross-reacts with human only), or rabbit anti-
SV40 T (diluted 1:200; Santa Cruz 20800) antibodies for
one hour and horseradish-peroxidase labeled secondary
antibodies for one hour, and visualized by chemilumines-
cent detection in Western Lightning (Perkin-Elmer, Bos-Page 4 of 17
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Rochester, NY). Developed films were placed on transmit-
ted white light, and then images were captured using a Q
Imaging CCD camera and processed using NIH ImageJ.
Results
Total bladder cancer volume determined by flat panel 
detector-based cone beam computed tomography
To monitor BC volume in male UPII-SV40T mice, animals
were scanned using an FPDCT scanner at three different
times points four weeks apart. Coronal, sagittal, and axial
scans of UPII-SV40T animals depicted bladders filled with
contrast agent and allowed visualization of tumors, noted
as filling defects (Fig. 1A). Three-dimensional reconstruc-
tion of the FPDCT scans with pseudo-colored tumors
overlaid indicated the exophytic nature of the BC (Fig. 1B,
D). At necropsy, it was noted that large exophytic mouse
BCs (epithelial opacity, Fig. 1C) were fed by extensive vas-
cular networks grossly visible though the bladder wall.
A montage of axial slices through the bladder illustrates
the presence of contrast agent in the bladder as a positive
image on a mostly negative field (Fig. 2A). Exophytic
tumors protruding into the lumen from the bladder wall
were visible beginning at 24 weeks of age in the UPII-
SV40T mice (arrows, Fig. 2A). Filling defects were not
observed at 16 and 20 weeks, although carcinoma in situ
is present in UPII-SV40T mice as early as one month [14].
Histological analysis of UPII-SV40T bladders shows the
exophytic tumor growth (Fig. 2B). Castration changes the
morphology of bladder tumors compared to the tumors
seen in intact animals, but urothelial dysplasia is persist-
ent in castrated mice (Fig. 2B).
In intact and castrate + DHT animals, individual tumors
continued to grow larger in an exophytic manner over an
eight-week period while tumors ceased exophytic growth
in animals castrated at 24 weeks (Fig. 2A, 3). In fact,
tumors in 5 of 8 castrated animals decreased in size. Cas-
trated animals implanted with slow-release DHT pellets
appeared to have slightly slowed tumor growth between
the castration/pellet implantation at 24 weeks and the fol-
lowing FPDCT scan at 28 weeks, but tumor growth con-
tinued 4 weeks after castration and DHT implantation
(Fig. 3). At 24 weeks (immediately before sham, castra-
tion, and castration/DHT implantation procedures),
mean tumor volumes were 6.5 ± 2.3, 6.5 ± 2.2, and 7.7 ±
2.6 mm3, respectively. At 32 weeks, mean tumor volumes
were 31.4 ± 8.4 mm3 for 9 intact animals, 4.3 ± 1.7 mm3
for 8 castrated animals, and 28.9 ± 7.2 mm3 for 6 castrate/
DHT animals. Intact and castrate/DHT mean tumor vol-
umes at 32 weeks were not different, p = 0.8055 (one-way
ANOVA, JMP 6.0.3, SAS Institute, Inc.); however, castrate
mean tumor volumes were significantly different from
intact, p = 0.0071, and castrate/DHT, p = 0.0233.
Expression of androgen receptor in human urothelium and 
bladder cancer
Of the ten human BC samples examined, BC showed 50%
positive staining for the AR (Fig. 4A, B). There were 15 foci
of benign urothelium included on these slides; 10 were
positive and 5 were negative for AR. The positively stained
benign urothelium had nuclear staining for the AR in cells
above the basal layer (Fig. 4C).
Dihydrotestosterone stimulates proliferation of bladder 
cancer cells in vitro
LNCaP, a high AR-expressing androgen responsive pros-
tate cancer cell line, and PC3, a low AR-expressing andro-
gen-independent prostate cancer cell line, were
respectively used as positive and negative controls for
DHT-stimulated cell proliferation. Human BC cell lines
TCCSUP and J82 treated with DHT had increased cell pro-
liferation compared to controls, despite neither cell line
expressing very much or any AR (Fig. 4D). Mouse BC
explant MMUST from a male UPII-SV40T also responded
to DHT treatment with an increase in cell proliferation,
again despite a lack of AR protein expression (Fig. 4D).
Microvessel and thrombospondin-1 distribution in UPII-
SV40T bladder
Since the exophytic nature of the UPII-SV40T BC suggests
a role for angiogenesis, 5 μm sections of UPII-SV40T
mouse bladders at 32 weeks of age were stained for CD34,
a marker of microvessels, or TSP1. Animals had been
either sham-operated, castrated and administered DHT,
or castrated at 24 weeks of age. CD34 was found to be
present in the stroma as well as in the BC of sham-oper-
ated and castrated + DHT animals. Castrated animals
expressed CD34 only in the stroma (Figure 5). Secreted
TSP1 was found to be expressed in the bladder stroma of
all animals, but TSP1 expression in the urothelium was
greater in castrated animals when compared to intact ani-
mals (Figure 6). Staining for SV40T was performed to con-
firm that uroplakin II promoter was not androgen
responsive: SV40T is present in the urothelial cells of both
intact and castrated animals (Figure 6). Additional immu-
nohistochemical staining for AR confirmed the urothelial
presence of AR in both intact and castrated animals (Fig-
ure 6).
Thrombospondin-1 expression in normal bladder and 
tumor
Proteins from whole male mouse bladders (20–24 weeks
of age) were subjected to western blot analysis. The molec-
ular weight of TSP1 expressed in mouse and human blad-
ders was slightly less than 50 kDa. Wild-type mouse
expressed significantly more TSP1 than transgenic UPII-
SV40T in the bladder (p = 0.0326, Fig. 7A; paired, two-
tailed, student's t-test). Castration of UPII-SV40T male
animals resulted in a modest (but not statistically signifi-Page 5 of 17
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FPDCT scans, 3-dimensional reconstruction, and necropsy photo of UPII-SV40T transgenic mouseigure 1
FPDCT scans, 3-dimensional reconstruction, and necropsy photo of UPII-SV40T transgenic mouse. (A) Coronal, 
sagittal, and axial CT sections of a bladder with exophytic tumor. (B) Overlay of coronal, sagittal, and axial CT slices; overlaid 
CT slices with green pseudo-colored tumor; 3D rendering of high contrast areas – skeleton and contrast-filled bladder – with 
green pseudo-colored exophytic tumor. Insets: Magnified bladder sections of CT overlay, overlay with pseudo-colored tumor, 
and 3D rendering of high contrast areas with pseudo-colored tumor, respectively. (C) A large exophytic bladder tumor 
(urothelial opacity) fed with an extensive network of blood vessels is visualized by backlighting the bladder. (D) 3D pseudo-
colored bladder tumor only.
BMC Urology 2008, 8:7 http://www.biomedcentral.com/1471-2490/8/7cant) increase in TSP1 expression in bladder protein at
days 2–7 post-castration compared to their intact counter-
parts (Fig. 7B). Seventeen days after castration in UPII-
SV40T, TSP1 bladder protein expression was increased
3.8-fold (p = 0.0154) compared to intact animals (Fig. 7B,
C). GAPDH immunoblot controls verified equal loading
of samples (Fig. 7C).
Paired normal and BC frozen biopsies from ten male
patients were also examined for expression of TSP1 pro-
tein by western blot analysis. TSP1 expression was greater
in 8 (specimens 2, 3, 4, 5, 6, 7, 9, 10; Fig. 8A) of the nor-
mal bladder specimens compared to the paired BC speci-
men. One tumor/normal tissue pair showed no detectable
TSP1 at all (specimen 1), while another tumor/normal tis-
CT and histological sections of mouse bladders with space-filling tumorsFigure 2
CT and histological sections of mouse bladders with space-filling tumors. (A) Sequential whole body axial slices from 
FPDCT scans taken at three time points (24, 28, and 32 weeks of age) were cropped to select the bladder, with the lumen 
filled with a radiopaque agent and appearing lighter than the surrounding tissue. Areas of radiopaque exclusion in the lumen are 
indicated with arrows. Animals were either sham-operated, castrated + DHT pellet, or castrated within one week after the ini-
tial 24-week FPDCT scan. Tumor volumes were calculated from the difference in area in each slice after thresholding to select 
the bladder area and the Omnipaque™-filled area. (B) Hematoxylin/eosin stained sections of bladders from UPII-SV40T male 
intact, castrate + DHT pellet, and castrate mice. 100× original magnification.Page 7 of 17
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the tumor compared to the normal tissue (Fig. 8A).
The hormonal status of these patients was unknown. AR
protein expression was evaluated in these samples by
western blot analysis (anti-AR, Dako clone AR441). AR
expression was higher in patient samples in which TSP1
expression was higher, except in specimen 1 where AR
expression was actually higher in the tumor sample and
TSP1 was not detected in either the normal or BC sample
(data not shown). However, among the patient speci-
mens, TSP1 expression was significantly greater in normal
tissue than in BC (p = 0.009; paired, two-tailed, student's
t-test) while AR expression was not significantly different
(p = 0.125). GAPDH loading controls verified equal load-
ing of protein samples (data not shown).
A panel of mouse tissue lysates was investigated for TSP1
expression (Fig. 8B). Brain, lung, pancreas, liver, spleen,
intestine, skin, testes, prostate, ovary, uterus, and kidney
(lanes 2, 3, 4, 5, 6, 8, 9, 10, 11, 13, 14, 15, respectively) all
had detectable levels of a TSP1 fragment slightly smaller
than 50 kDa. Brain (lane 2) also expressed TSP1 fragments
of ~ 140 kDa, 70 kDa, and a doublet present between
37–50 kDa. Pancreas (lane 4) also expressed this doublet
band between 37–50 kDa. Only prostate and uterus
(lanes 11 and 14, respectively) expressed an even smaller
TSP1 fragment less than 37 kDa. TSP1 expression in
mouse bladder is shown in Figure 5C and was not
included in this tissue panel. The ~ 450 kDa trimeric form
of TSP1 was not detectable on a gradient gel under dena-
turing conditions (data not shown).
Discussion
Non-invasive in vivo imaging of small animals minimizes
the number of animals used in experiments, increases the
information about real-time phenomena unlike post-
mortem analyses, and demonstrates the effects of inter-
ventions within a given host. Currently, however, many in
vivo imaging instruments function on an image acquisi-
Bladder cancer growth in UPII-SV40T transgenic male miceFigure 3
Bladder cancer growth in UPII-SV40T transgenic male mice. Animals were anesthetized, injected with radiopaque 
agent via tail-vein, and submitted to FPDCT scanning for a total of 3 longitudinal sessions. Data sets were analyzed with Amira 
and NIH ImageJ to identify tumors and quantify tumor volumes. Tumor volumes for intact (n = 9), castrate (n = 8), castrate + 
DHT (n = 6) are indicated. Values are mean ± SE. p = 0.0071*, p = 0.0233** vs. castrate (one-way ANOVA, JMP 6.0.3, SAS 
Institute, Inc.).Page 8 of 17
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AR expression and DHT response in bladderFigure 4
AR expression and DHT response in bladder. Nuclear AR expression (brown-stained cells) in (A, B) human bladder can-
cer and (C) benign urothelium at 400× original magnification. Dako antibody clone AR441 was used for labelling. (D) MTT assay 
of human prostate cell lines (LNCaP and PC3), human bladder cancer cell lines (J82 and TCCSUP), and male mouse urothelial 
explant from UPII-SV40T animal (MMUST). Cells were treated with ethanol or DHT in ethanol vehicle for 72 hours prior to 
MTT assay. Experiments done in triplicate. Values are relative means ± SE. Western blot analysis using Santa Cruz 815 anti-
body was performed to determine AR expression.
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CD34 microvessel staining in mouse bladderFigure 5
CD34 microvessel staining in mouse bladder. Membrane expression of CD34 (brown staining) indicates the presence of 
microvessels. Male UPII-SV40T animals were sham-operated (intact), castrated and administered DHT, or castrated at 24 
weeks of age. Animals were euthanized and bladders harvested at 32 weeks of age. Tissue was formalin fixed and paraffin 
embedded. Examples of positive CD34 staining in the tumor urothelium are indicated with arrows. CD34 staining is also 
present in the stroma, corroborated by adjacent HE stained sections. Magnification: 200× original.
BMC Urology 2008, 8:7 http://www.biomedcentral.com/1471-2490/8/7
Page 11 of 17
(page number not for citation purposes)
Immunohistochemical staining of mouse bladderFigure 6
Immunohistochemical staining of mouse bladder. Male UPII-SV40T animals were sham-operated (intact) or castrated at 
24 weeks of age, and then animals were sacrificed at 32 weeks and bladders harvested, formalin-fixed, and paraffin embedded. 
The upper panel shows similar levels of SV40T staining in the urothelium of both intact and castrated animals. TSP1 expression 
is indicated by arrows in the center panels. AR is also expressed in the urothelium of both intact and castrated animals (anti-
AR, Santa Cruz 815). Magnification: 200× original.
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TSP1 protein expression in mouse bladderFigure 7
TSP1 protein expression in mouse bladder. Whole bladder lysates of sham-operated (intact) wild-type and sham-oper-
ated (intact) or castrated UPII-SV40T male mice were assayed and quantified for TSP1 expression by western blot analysis. (A) 
Relative bladder TSP1 protein expression in wild-type vs. UPII-SV40T mice. Values are relative means ± SE. For each group, n 
= 3. p = 0.0326*. (B) Relative bladder TSP1 protein expression in UPII-SV40T mice sacrificed 2, 3, 7, and 17 days after castra-
tion. Intact relative expression = 1. Values are relative means ± SE. For each group, n = 3. p = 0.0154** vs. intact. (C) Western 
blot of intact (n = 3) vs. 17-day castrate (n = 3) whole bladders from UPII-SV40T mice. TSP1 immunoblots were quantified. 
GAPDH control blot verified equal loading. P values determined by paired, two-tailed, student's t-test.
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TSP1 protein expression in human bladder and mouse tissuesFigure 8
TSP1 protein expression in human bladder and mouse tissues. (A) Protein lysates from paired human normal (N) and 
tumor (T) bladder tissues were also immunoblotted for TSP1. (B) Tissue protein lysates from mouse 1) skeletal muscle, 2) 
brain, 3) lung, 4) pancreas, 5) liver, 6) spleen, 7) heart, 8) intestine, 9) skin, 10) testes, 11) prostate, 12) seminal vesicle, 13) 
ovary, 14) uterus, 15) kidney.
BMC Urology 2008, 8:7 http://www.biomedcentral.com/1471-2490/8/7tion time-scale of 5 minutes, sufficient time for animal
movement resulting in blurred reconstructed data sets, to
hours, at which point animal recovery and longitudinal
studies become difficult. Considering the implications of
using conventional and commercially available in vivo
imaging techniques on animal welfare and longitudinal
studies, we utilized a unique FPDCT instrument that can
acquire 290 2D images in 10 seconds [34]. With this
instrument, multiple imaging sessions of individual ani-
mals are possible, permitting the monitoring of BC
growth in 23 animals presented here. Through the intra-
venous administration of Omnipaque®, a radiopaque
agent which is filtered from the bloodstream by the kid-
neys, excreted into urine, and collected in the bladder,
FPDCT scans allowed measurement of exophytic BC,
which were defined as areas of contrast exclusion (Fig. 1A,
B). Tumor volumes were quantifiable via image analysis
software used to label the exophytic tumors (contrast-
excluded areas; Figure 1B, D).
We observed that exophytic growth of mouse BC was
decreased by castration and restored by DHT administra-
tion. Mean tumor volumes for intact and castrate/DHT
animals were not different from each other but were sig-
nificantly different from the mean tumor volume of cas-
trate animals. This finding indicates that surgical
castration is sufficient to partially overcome the strong
tumorigenic drive of SV40 large T antigen. The UPII-
SV40T transgenic animal reliably produces BC that mim-
ics BC in humans [14] and is free from complications
associated with BC models using chemical carcinogens,
which are metabolized by an androgen-influenced P450
system in the liver and urothelium [5-9]. It has long been
hypothesized that sexual differences in steroid hormones
or their receptors may contribute to the difference in BC
incidence between the genders in humans and animals,
although previous in vivo studies of steroid hormones and
BC have relied on chemical carcinogen models [10-13].
With regard to the sexual difference in the incidence of
BC, AR expression has been investigated in bladder tissue.
AR is expressed in normal mouse [38], rat [39-41], and
human [42] bladder epithelia as well as human BC cell
lines [13,43]. Human BC biopsies from males and
females had a greater concentration of AR than normal
human urothelium [44], indicating that AR might be use-
ful as a diagnostic marker for BC. However, the same
study [44] also showed that the AR levels decreased with
increasing tumor grade in BC, which has been corrobo-
rated by steroid binding [45] and immunohistochemical
[46] studies. This decreased expression of AR in higher
grade tumors may indicate a more poorly differentiated
cell type or, as in prostate cancer, a transition to an andro-
gen-independent state. In addition, it should be noted
that experiments by Guerini et al. [47] indicate that steroid
hormone receptors other than AR may be activated by
DHT and its metabolites. As such, we investigated the in
vitro growth of BC cell lines and UPII-SV40T urothelial
explants, which express little or no AR, and found that
DHT was still able to increase proliferation. We were also
able to detect AR in the bladders of intact and castrated
UPII-SV40T mice but did not notice a significant differ-
ence in the expression levels. Furthermore, Miyamoto et
al. [13] showed that DHT treatment of BC cell lines stim-
ulated proliferation in vitro, and this effect was abrogated
by the anti-androgen hydroxyflutamide; ARKO male mice
treated with BBN did not develop BC, but 25% of BBN-
induced ARKO males developed BC. Taken together,
Miyamoto's data suggest the potential for two separate
mechanisms: 1) an androgen-mediated, classical AR sign-
aling pathway, and 2) an androgen-regulated, non-AR
dependent signaling mechanism in BC. The data pre-
sented here support the latter mechanism without contra-
dicting the possibility of a classical AR-dependent
pathway.
We speculated that the exophytic growth might be
dependent on neo-vascularization. Because there were
such significant effects on the morphology of the bladder
tumors, microvessel density counts could not be per-
formed in a systematic manner; bladder tumors could not
be compared to normalized urothelium. However, CD34
expression was noted in the bladder stroma and BC
urothelium of intact and castrate + DHT animals whereas
CD34 was only present in the bladder stroma of castrated
animals. The absence of CD34 staining for microvessels in
the BC of castrated animals indicates that there may be
less angiogenesis in castrated animals compared to their
intact and DHT augmented counterparts. Additionally,
the anti-angiogenic factor, TSP1, which plays a strong ang-
iogenic-inhibitory role and whose expression is sup-
pressed by androgens, was investigated. The TSP1
promoter has been shown to contain a hormone response
element that is sensitive to testosterone agonist adminis-
tration [32]. In addition, the same study also found that
castration of rats increases TSP1 expression and decreases
microvessel density counts in the prostate [32]. Metastatic
prostate cancer patients treated with androgen depriva-
tion therapy expressed a significantly higher TSP1 immu-
noreactivity in prostatic adenocarcinoma when compared
to other metastatic prostate cancer patients who did not
receive hormonal therapy [48]. Testosterone administered
in vitro to breast cancer cells has been shown to decrease
TSP1 expression at the mRNA and protein levels, and this
effect can be inhibited by pre-incubation with the anti-
androgen flutamide [33]. Western blot analysis of intact
male mouse bladders indicated that wild-type animals
expressed more of the ~ 50 kDa TSP1 fragment (previ-
ously shown to have a neovascularization inhibitory role
in vivo) [26] than their tumor-bearing UPII-SV40T trans-Page 14 of 17
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TSP1 in the exophytic growth of UPII-SV40T BC. Further-
more, castration increased the TSP1 protein expression in
both wild-type and transgenic animal bladders. It is inter-
esting to note that mouse uterus expressed the ~ 25 kDa
fragment of TSP1, which has previously been shown to
have pro-migratory and neovascularization effects [26].
This neovascularization fragment of TSP1 may be of use to
the uterus during the estrus cycle by providing a mecha-
nism for vascular enrichment.
We examined TSP1 expression in high grade and high
stage human BC. Campbell et al. [31] showed reduced
TSP1 expression in both high and low grade BC and sug-
gested that the switch from an anti-angiogenic to ang-
iogenic phenotype occurs early in BC development. The
data suggest that down-regulation of TSP1 secretion in
bladder is important in facilitating this switch. In addi-
tion, prostate biopsies indicated that patients with meta-
static prostate cancer had significantly less TSP1
expression than patients with localized prostate cancer,
who also had significantly lower TSP1 expression than
patients with benign prostatic hyperplasia [48]. We exam-
ined the protein expression of TSP1 in human BC paired
with normal bladder tissue from the same patients and
found that the ~ 50 kDa TSP1 anti-angiogenic fragment is
decreased in human urothelial cancer tissue. Eight of the
ten paired samples had greater TSP1 protein expression in
the normal tissue compared to the BC. One paired sample
did not express TSP1 in either the normal or tumor tissue,
and one paired sample showed higher TSP1 expression in
the BC rather than the normal tissue. Previous immuno-
histochemical analysis of human BC indicated that poorly
differentiated tumors expressed lower levels of TSP1 [49]
and that tumors expressing less TSP1 at presentation were
more likely to become invasive and/or metastatic [30].
Grossfeld et al. [29] found that patients with low TSP1
expression in BC had an increased risk of recurrence and
decreased survival and that the expression of TSP1 was
dependent on p53 expression: 96% of tumors with
wildtype p53 expressed moderate to high levels of TSP1
protein, and only 58% of tumors with altered p53 protein
overexpressed TSP1.
We do not mean to overstate the role of TSP1 in this
mouse model of BC. The data presented here are mainly
correlative, and, certainly, more experimentation to exam-
ine the mechanisms involved in androgen regulation of
TSP1 is required. Furthermore, it is not our intention to
assert that TSP1 is the only protein involved in this com-
plex tumor model. Rather, TSP1 expression was investi-
gated since it has previously been shown to be
hormonally-regulated and plays a negative role in angio-
genesis. Hormonal manipulation, specifically castration,
can alter the expression of a host of other proteins
involved in proliferation and/or angiogenesis. This report
presents data that support an androgen-regulated TSP1
hypothesis, which may be important in the angiogenic
capabilities of BC.
The UPII-SV40T model system employed here bypasses
the need for a chemical carcinogen, which confounds
analysis of androgen effects, and FPDCT allows longitudi-
nal monitoring of tumor growth. Androgens increase
tumor cell growth in vitro and in vivo and decrease TSP1
expression, possibly explaining the therapeutic effect of
castration. This effect was seen even in cellular targets
lacking detectable AR, indicating a stimulatory effect for
androgens that may work through mechanisms other
than AR e.g. other steroid receptors or non-steroid recep-
tor mechanisms. Androgen stimulation may contribute to
the increased incidence of BC in men, and androgenic
suppression may be an avenue for BC prevention therapy
via anti-androgens, LHRH agonists, and/or 5-alpha-
reductase inhibitors. Others have reported changes in
TSP1 expression in response to androgens in prostate and
breast cancer. This report is the first to show modulation
of TSP1 by androgen manipulation in a non-hormonal
cancer.
Conclusion
The UPII-SV40T model system employed here bypasses
the need for a chemical carcinogen, which confounds
analysis of androgen effects, and FPDCT allows longitudi-
nal monitoring of tumor growth. Androgens increase
tumor cell growth in vitro and in vivo and decrease TSP1
expression, possibly explaining the therapeutic effect of
castration. This effect was seen even in cellular targets
lacking detectable AR, indicating a stimulatory effect for
androgens that may work through mechanisms other
than AR e.g. other steroid receptors or non-steroid recep-
tor mechanisms. Androgen stimulation may contribute to
the increased incidence of BC in men, and androgenic
suppression may be an avenue for BC prevention therapy
via anti-androgens, LHRH agonists, and/or 5-alpha-
reductase inhibitors. Others have reported changes in
TSP1 expression in response to androgens in prostate and
breast cancer. This report is the first to show modulation
of TSP1 by androgen manipulation in a non-hormonal
cancer.
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